Advertisement
Research Article

Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer

  • Malek B. Hannouf,

    Affiliation: Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada

    X
  • Chander Sehgal,

    Affiliation: Richard Ivey School of Business, University of Western Ontario, London, Ontario, Canada

    X
  • Jeffrey Q. Cao,

    Affiliations: Richard Ivey School of Business, University of Western Ontario, London, Ontario, Canada, Department of Radiation Oncology, London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada

    X
  • Joseph D. Mocanu,

    Affiliation: Richard Ivey School of Business, University of Western Ontario, London, Ontario, Canada

    X
  • Eric Winquist,

    Affiliation: Department of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada

    X
  • Gregory S. Zaric mail

    gzaric@ivey.uwo.ca

    Affiliations: Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada, Richard Ivey School of Business, University of Western Ontario, London, Ontario, Canada

    X
  • Published: June 20, 2012
  • DOI: 10.1371/journal.pone.0038557

Reader Comments (0)

Post a new comment on this article